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Acute Reduction of Microglia Does Not Alter Axonal
Injury in a Mouse Model of Repetitive
Concussive Traumatic Brain Injury
Rachel E. Bennett and David L. Brody
Abstract
The pathological processes that lead to long-term consequences of multiple concussions are unclear. Primary mechanical
damage to axons during concussion is likely to contribute to dysfunction. Secondary damage has been hypothesized to be
induced or exacerbated by inflammation. The main inflammatory cells in the brain are microglia, a type of macrophage. This
research sought to determine the contribution of microglia to axon degeneration after repetitive closed-skull traumatic brain
injury (rcTBI) using CD11b-TK (thymidine kinase) mice, a valganciclovir-inducible model of macrophage depletion. Low-
dose (1mg/mL) valganciclovir was found to reduce the microglial population in the corpus callosum and external capsule by
35% after rcTBI in CD11b-TK mice. At both acute (7 days) and subacute (21 days) time points after rcTBI, reduction of the
microglial population did not alter the extent of axon injury as visualized by silver staining. Further reduction of the microglial
population by 56%, using an intermediate dose (10mg/mL), also did not alter the extent of silver staining, amyloid precursor
protein accumulation, neurofilament labeling, or axon injury evident by electron microscopy at 7 days postinjury. Longer
treatment of CD11b-TK mice with intermediate dose and treatment for 14 days with high-dose (50mg/mL) valganciclovir
were both found to be toxic in this injury model. Altogether, these data are most consistent with the idea that microglia do not
contribute to acute axon degeneration after multiple concussive injuries. The possibility of longer-term effects on axon
structure or function cannot be ruled out. Nonetheless, alternative strategies directly targeting injury to axons may be a more
beneficial approach to concussion treatment than targeting secondary processes of microglial-driven inflammation.
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Introduction
While 91% of athletes will recover from symptomsof concussion within 1 week, there is increasing awareness
of the long-term consequences of suffering one or more concus-
sions, particularly among retired professional football players and
boxers.1–9 While the origins of these long-term effects are un-
known, studies in postmortem samples from human traumatic brain
inury (TBI) and from individuals known to have received multiple
concussive injuries have consistently revealed the presence of de-
generating axons and inflammation months to years after the initial
insult.10–17 These processes have also been viewed in vivo using
diffusion tensor imaging to visualize white matter (WM) injury in
concussed individuals and using positron emission tomography
ligands to the peripheral benzodiazepine receptor to confirm the
presence of microglia and macrophage in TBI patients.18–24 Our
group and others have developed mouse models of mild repetitive
concussion and have also observed the presence of injured axons
within WM and accumulation of glial cells.25–30 Interestingly, in
our repetitive closed-skull injury model, we have observed that
accumulation and activation of microglia within WM regions
precedes the degeneration of axons as visualized by silver stain-
ing.29 Altogether, these data have led us to hypothesize that mi-
croglia and macrophage may contribute to secondary axon injury
processes after concussion.
To address this hypothesis we used a CD11b-TK (thymidine ki-
nase) transgenic mouse model to reduce the numbers of microglia
within the corpus callosum (CC) and external capsule (EC). CD11b-
TK mice express a mutated form of TK from herpes simplex virus
(HSV) under the CD11b promoter.31 When mice are treated with the
nucleotide analog, ganciclovir, or its more soluble prolog, valganci-
clovir, the drug is metabolized by cells expressing TK into a toxic
product that leads to cell death. Valganciclovir will only become toxic
to CD11b+ cells expressing HSV TK and is not toxic to genetically
wild-type (WT) mice, such as the CD11b-TK- /- littermate controls.
Research from other groups has shown that daily intraperitoneal (i.p.)
injection of ganciclovir into these mice effectively depletes circu-
lating macrophages and prevents proliferation of microglia in the
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brain.31,32 Here, we show that intracerebroventricular (i.c.v.) delivery
of different doses of valganciclovir resulted in a dose-dependent re-
duction of microglial cells in mice subjected to repetitive closed-skull
injury. The effects of reducing the microglial population on both
acute and subacute axon degeneration after injury were assessed by
silver staining. We found that reducing the number of microglial/
macrophage cells had little effect on the amount of axon degeneration
at either 7 or 21 days postinjury.
Methods
Animals
CD11b-TK mice were acquired from Jean-Pierre Julien at Laval
University (Que´bec City, Que´bec, Canada). CD11b-TK mice express
HSV TK under the CD11b promoter expressed in microglia and
macrophage. Male CD11b-TK+ /- founder mice were crossed to
C57bl/6j female mice (catalog no.: 000664; JAX; The Jackson La-
boratory, Bar Harbor, ME). The resulting offspring were genotyped
using previously published methods.31 Mice carrying the CD11b-TK
transgene were termed CD11b-TK+ /- mice, and littermates not car-
rying the transgene were termed CD11b-TK- /- mice and are genet-
ically WT. All mice were housed under a 12-h light/dark cycle and
given food and water ad libitum in accord with the protocols of the
animal studies committee at Washington University (St. Louis, MO).
Osmotic pumps
Alzet osmotic pumps (catalog nos.: 1002 and 2004; DURECT
Corporation, Cupertino, CA) with flow rates of 0.25lL/h were used
for these experiments. A complete description of pump assembly can
be found elsewhere.33 Briefly, cannula tubing (catalog no.: 312VT)
and osmotic pump connector cannula (catalog no.: 3280PM/SP, cut
2.5mm below pedestal) were purchased from Plastics One, Inc.
(Roanoke, VA). Pump reservoirs were filled with either valganci-
clovir (catalog no.: SML0191; Sigma-Aldrich, St. Louis, MO) in
0.9% sterile saline (NaCl) or with 0.9% NaCl. Osmotic pump flow
tubes were stripped of their plastic caps, and the flow tubes were
connected to 1-in lengths of cannula tubing. The other end of the
cannula tubing was attached to the osmotic pump connector cannula.
Table 1. Primer Sets Used for qPCR
Encoded protein Accession no. Direction 5¢-3¢ Amplicon size (bp)
PGK1 NM_008828.2 Forward ctccgctttcatgtagaggaag 117
Reverse gacatctcctagtttggacagtg
GAPDH NM_008084 Forward catggacttccgtgttccta 55
Reverse gcggcacgtcagatcca
HPRT1 NM_013556.2 Forward cctaagatgagcgcaagttgaa 86
Reverse ccacaggactagaacacctgctaa
IL1-b NM_008361.3 Forward acggaccccaaaagatgaag 139
Reverse ttctccacagccacaatgag
IL-6 NM_031168.1 Forward caaagccagagtccttcagag 150
Reverse gtccttagccactccttctg
iNOS NM_010927 Forward tggtccgcaagagagtgct 108
Reverse cctcattggccagctgctt
CCL2 NM_011333 Forward aggtgtcccaaagaagctgta 85
Reverse atgtctggacccattccttct
TNF-a NM_013693 Forward cttctgtctactgaacttaggg 134
Reverse caggcttgtcactcgaattttg
qPCR, quantitative polymerase chain reaction; PGK1, phosphoglycerate kinase 1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HPRT1,
hypoxanthine phosphoribosyltransferase 1; IL, interleukin; iNOS, inducible nitric oxide synthetase; CCL2, chemokine (C-C motif ) ligand 2; TNF-a,
tumor necrosis factor alpha; bp, base pairs.
FIG. 1. Experimental design. CD11b-TK + / - or CD11b-TK- / - controls were treated with either valganciclovir or saline by in-
tracerebroventricular osmotic pump for 7 days preceding injury. Pumps were then removed, and a closed-skull or sham injury was
performed (day 0). Twenty-four hours later, a second injury was delivered. Pumps were immediately reimplanted, and drug or saline
treatment was resumed for another 7 (acute time point) or 21 days (subacute time point). TK, thymidine kinase.
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FIG. 2. Treatment of CD11b-TK+ /- micewith intracerebroventricular low-dose valganciclovir (1mg/mL) reducesmicroglia, but does not
affect silver staining 7 days after repetitive closed-skull traumatic brain injury. Iba-1 staining in treated CD11b-TK- /- (A andC) and CD11b-
TK+ /- (B and D) mice. (C and D) Higher magnification views of Iba-1 staining in corpus callosum ipsilateral to injury (region boxed in A,
outlined with red dashed line). Silver staining in valganciclovir-treated CD11b-TK- /- (E) and CD11b-TK+ /- (F) mice. (G) Stereological
quantification of Iba-1-positive microglia in CD11b-TK+ /- mice shows a*35% reduction, compared to controls (one-tailed Student’s t-test,
**p< 0.01; dashed line indicates sham levels). (H) Silver staining in white matter was unchanged. A.U., arbitrary units; n.s., not significant.
Error bars represent standard error of the mean. TK, thymidine kinase. Color image is available online at www.liebertpub.com/neu
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The entire assembly was primed by placing the reservoir in conical
tubes containing 0.9% NaCl, and tubes were stored at 37C for 36–
48 h before implantation. This longer priming step was deemed
necessary because cannula tubing was not filled with drug—
preliminary experiments with 1.5% Evan’s blue in saline showed
that it takes*36 h for solution to travel from the reservoir of 14-day
0.25-lL/h pumps to the end of the cannula under these conditions.
Surgical procedures
Six to 8-week-old CD11b-TK+ / - and WT littermate controls
were used in all experiments. Mice were randomly assigned to
either NaCl or valganciclovir treatment groups. For implantation of
osmotic pumps, mice received inhaled isofluorane anesthesia and
the head was fixed in a stereotaxic frame. Temperature was regu-
lated using a heat pad (Sun Microsystems II; Sun Microsystems,
Inc., Santa Clara, CA). A midline incision was made to expose the
skull and a small (0.9-mm) burr hole was drilled contralateral to the
repetitive closed-skull TBI (rcTBI) impact site at anterior/posterior
(A/P) - 0.84mm relative to bregma, mediolateral (ML) + 1.5mm
relative to mid-line at bregma. Pumps were implanted subcutane-
ously, and a drop of cyanoacrylate glue was applied to the bottom of
the plastic portion of the cannula. A cannula guide was used to drive
the metal osmotic pump connector cannula through the burr hole
into the lateral ventricle (dorsoventricular - 2.5mm) and to hold it
firmly in place for 1–2min while the glue set. The top of the can-
nula was trimmed, and the incision was sutured closed. Mice re-
ceived antibacterial ointment and were placed on a heat pad for
recovery. Once animals were ambulatory, they were housed indi-
vidually to prevent cagemates from tampering with pumps.
Seven days after pump implantation, pumps were removed,
fitted with new cannulas, placed in individual conical tubes
containing 0.9% NaCl and 0.01% sodium azide (NaN3), and
stored at 37C. Mice then received two repetitive closed-skull
injuries 24 h apart, as described previously.29 Briefly, a rubber tip
was fitted on an electromagnetic impact device that was used to
impact the skull with the tip centered at A/P - 1.8, ML - 1.5
bregma to a depth of - 3.3 mm. Sham-injured mice underwent the
same surgical procedures, but did not receive impacts. Im-
mediately after the second impact, pumps were rinsed in filtered
phosphate-buffered saline (PBS) and reimplanted as described
above to resume drug delivery.
Histology
Mice were sacrificed by isofluorane overdose and decapitation
either 7 or 21 days after the first repetitive closed-skull injury. All
mice were perfusedwith 10mL of cold 0.03% heparin in PBS. Brains
were then removed and placed in 4% paraformaldehyde (PFA) for
24–48 h at 4C and then in 30% sucrose in PBS for 24–48 h at 4C.
Once equilibrated in sucrose, they were frozen on dry ice and sliced
into 50-lm sections on a freezing microtome. Serial sections were
collected in cryoprotectant (30% ethylene glycol, 15% sucrose, and
0.03M of phosphate buffer) and stored at 4C until use.
Immunohistochemistry (IHC) was performed on sections to vi-
sualize rabbit polyclonal anti-Iba-1 (catalog no.: 019-19741; Wako
Chemicals USA, Inc., Richmond, VA), chicken polyclonal anti–glial
fibrillary acidic protein (GFAP; catalog no.: ab4674; Abcam, Cam-
bridge, MA), rabbit polyclonal anti–beta-amyloid precursor protein
(b-APP; catalog no.: 512700; Invitrogen, Carlsbad, CA), or mouse
monoclonal RM014 (catalog no.: 34-1000; Novex; Life Technolo-
gies, Carlsbad, CA). For this, sections were washed 3 times for 5min
in Tris-buffered saline (TBS), incubated in 0.03% H2O2 for 10min,
washed 3 times for 5min in TBS, then blocked for 30min in either
3% normal goat serum (NGS; catalog no.: S-1000; Vector La-
boratories, Burlingame, CA) or 3% normal donkey serum (catalog
no.: 017-000-121; Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA) in 0.25% Triton-X TBS (TBS-X). After
blocking, primary antibodies (Abs) were applied at a 1:1000 di-
lution in blocking solution and incubated overnight at 4C with
gentle shaking. The following day, sections were again washed,
incubated 1 h at room temperature (RT) in either biotinylated goat
FIG. 3. Low-dose valganciclovir (1mg/mL), but not saline,
reduces microglia and has no effect on silver staining 7 days after
injury in an independent cohort of mice. (A) Iba-1 staining and (B)
silver staining in corpus callosum and external capsule of
CD11b + / - and CD11b - / - mice receiving either drug or vehicle
treatment. A.U., arbitrary units; n.s., not significant. *p < 0.05;
**p < 0.01. Dashed line indicates sham levels. Error bars represent
standard error of the mean. TK, thymidine kinase. Color image is
available online at www.liebertpub.com/neu
FIG. 4. High-dose (50mg/mL) valganciclovir treatment was toxic in CD11b-TK + / - mice 7 days postinjury. (A) An Iba-1-stained
section near the cannula site (dashed line) shows depletion of microglia, but also numerous microhemorrhages (arrows). (B) Cresyl
violet staining in a section posterior to valganciclovir injection shows extensive tissue loss in the hippocampus and thalamus (dashed
oval). TK, thymidine kinase. Color image is available online at www.liebertpub.com/neu
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anti-rabbit immunoglobulin G (IgG; catalog no.: BA-1000; Vector
Laboratories) or biotinylated donkey anti-chicken IgG (catalog no.:
703-065-155; Jackson ImmunoResearch) secondary Abs were di-
luted 1:1000 in TBS-X, washed again, then incubated in 1:400
avidin-biotin complex (ABC) reagent (catalog no.: PK-6100;
Vector Laboratories) in TBS for another hour. Finally, sections
were washed and placed in 3-3¢-diaminodebzidine tetra-
hydrochloride (DAB; catalog no.: D5905) for 5–6min. After de-
velopment in DAB, sections were washed, placed on slides, and
allowed to air dry, then cover-slipped with cytoseal (catalog no.:
8312-4; Richard-Allan Scientific Co., Kalamazoo, MI). For RM014
staining specifically, the following modifications to the above-de-
scribed protocol were made: 1) Sections were blocked in 1:10
mouse serum; 2) the primary Ab was incubated 1:2 with biotiny-
lated goat anti-mouse Fab IgG (catalog no.: 115-007-003; Jackson
ImmunoResearch) for 20min before application to the sections
overnight; and 3) the secondary Ab was unnecessary, and sections
were immediately incubated in ABC on day 2.
Adjacent sets of floating sections were subjected to silver
staining (catalog no.: PK301, NeuroSilver Kit II; FD Neuro-
technologies, Inc., Elliot City, MD), following the manufacturer’s
instructions with minor modifications, as previously reported.29
Sections were incubated for 5 days in PFA before silver staining
and were only incubated in solution C once for 2min.
For cresyl violet staining, sections were rinsed in TBS twice for
5min, then mounted on glass slides. Once air-dried, they were
placed in cresyl violet solution (catalog no.: PS102-1; FD Neuro-
tech) for 5min, then rinsed and cover-slipped, following manu-
facturer’s protocol.
For terminal deoxynucleotidyl transferase dUTP nick end
labeling/neuronal nuclear antigen (TUNEL-NeuN) double-
immunofluorescence (IF), 50-lm free-floating sections were washed
with TBS and incubated for 15min with 0.02mg/mL of proteinase K
in TBS. A positive control for TUNEL labeling was generated by
incubating a tissue section in 1lg/mL of DNAse I for 20min at RT.
Sections were then washed and blocked in 3% NGS in TBS-X for
30min and incubated overnight in 1:1000 rabbit polyclonal anti-
NeuN (catalog no.: ABN78; Millipore, Billerica, MA) in blocking
solution. The following day, sections were washed and incubated
in donkey anti-rabbit IgG cyanine 3 (catalog no.: 711-165-152;
FIG. 5. Valganciclovir dose response in CD11b-TK mice 7 days postinjury. Iba-1-stained whole sections (A, C, and E) and higher-
magnification images (box A) corresponding to the region of interest assessed for iba-1 depletion by stereology (outlined with red dashed
line; B, D, and F). CD11b-TK+ /- mice treated with 2 (A and B), 5 (C and D), or 10mg/mL (E and F) of valganciclovir. Microglial
depletion is most prominent ipsilateral to cannulation and drug delivery (right). Arrowheads indicate region of microglial reduction in
cortex of hemisphere opposite drug infusion. TK, thymidine kinase. Color image is available online at www.liebertpub.com/neu
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Jackson ImmunoResearch) for 1 h at RT in the dark. Sections were
then washed, mounted on glass slides, and allowed to air dry for 1 h.
A hydrophobic barrier was drawn with a PAP pen around each
section, and TUNEL staining was performed according to the
FragEL DNA Fragmentation Detection Kit (catalog no.: QIA39;
Calbiochem, San Diego, CA), following the manufacturer’s in-
structions. Double IF images were captured using a Zeiss Axiovert
200 laser scanning confocal microscope (Carl Zeiss AG, Oberko-
chen, Germany).
Electron microscopy
For electronmicroscopy, micewere perfusedwith 10mL of PBS-
Heparin followed immediately by 10mL of 1% PFA, and 1% glu-
taraldehyde in 0.1M sodium cacodylate buffer. Brains were fixed
using the same solution for 1 h, then sliced into two to three 1-mm
coronal slabs per mouse. Slabs were fixed for 5 days before being
incubated in 1% osmium tetroxide in sodium cacodylate buffer
overnight, followed by dehydration in ascending ethanol series, and
FIG. 6. Acute intermediate-dose valganciclovir (10mg/mL) reduces Iba-1, but not silver, staining in CD11b-TKmice 7 days after repetitive
closed-skull traumatic brain injury. Iba-1 staining in corpus callosum (outlined with red dashed line) in treated CD11b-TK- /- (A) and CD11b-
TK+ /- (B) mice. Silver staining in adjacent sections from CD11b-TK- /- (C) and CD11b-TK+ /- (D) mice. (E) Iba-1 was reduced by 56% in
CD11b-TK+ /- mice, compared to controls (one-tailed Student’s t-test, ***p<0.001; dashed line indicates sham levels). (F) No change in
silver staining was observed. A.U., arbitrary units; n.s., not significant. Error bars represent standard error of the mean. TK, thymidine kinase.
Color image is available online at www.liebertpub.com/neu
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embedding Polybed 812 (catalog no.: 08792; Polysciences, Inc.,
Warrington, PA). Embedding media were cured for 24 h in a des-
sicator and then in a 60C oven for 48 h. Semithin sections stained
with toluidine blue were prepared using glass knives to identify the
region of CC and EC ipsilateral to injury in each coronal slab. Tissue
was then thin sectioned (70–90 nm) on a Leica Ultracut E Micro-
tome (LeicaMicrosystems GmbH,Wetzlar, Germany), stained with
4% uranyl acetate and Reynolds lead citrate, and viewed on a JEOL
100C Electron Microscope ( JEOL, Tokyo, Japan). Three to five
grids were prepared from each block of tissue, and two blocks (1-
mm separation) were prepared from each animal. At least one grid
from each block was qualitatively assessed blinded to injury status
or genotype for evidence of axonal injury.
Stereological quantification and optical
density measurements
For all histological analysis, the region of interest (ROI) was
defined to include the CC and EC underlying the impact site. For
each mouse, the ROI began with the most anterior section con-
taining hippocampal dentate gyrus (DG) and ended with the most
posterior section containing CC fibers that cross mid-line. This
yielded 3–4 sections for analysis per animal. The mid-line served as
the medial boundary for the ROI, whereas the lateral boundary was
formed by drawing a horizontal line between the ventral hippo-
campus and dorsal thalamus in each coronal section.
Iba-1 stereological methods have been previously published.29
In brief, stereological quantification was performed blinded to geno-
type or drug treatment status using StereoInvestigator’s (Micro-
Brightfield) optical fractionator technique. The ROI was traced in
each section, and a 180· 180lm grid size and 80 · 80lm counting
frame was applied to determine the number of Iba-1-positive cells
in the CC and EC. This ensured that Gunderson’s coefficient of
error was < 0.1.
For quantification of silver staining, 20x images were captured
of all sections using the Olympus NanoZoomer Whole Slide Ima-
ging System (Olympus Corporation, Tokyo, Japan), as previously
reported.29 From the NanoZoomer file, 1.25 · .tiff images of
sections containing the DG of the hippocampus and CC were ex-
ported and opened in ImageJ software (National Institutes of
Health, Bethesda, MD). Background (gold color) was subtracted
from each image using the color splitter and image calculator
functions, so that only the gray-black silver deposits were visible.
ROIs were traced as described for Iba-1 analysis on 32-bit images
and measurements were taken to acquire mean gray values corre-
sponding to the intensity of silver staining (0–255) within each
ROI. Three serial sections were averaged from each animal to
produce a final silver staining value. Optical density measurements
were also taken blinded to genotype and drug treatment status.
For GFAP optical density measurements, 5x images of the CC
and EC were captured using the NanoZoomer. The .tiff files were
converted to 32-bit images in ImageJ, and positive signal on each
image was selected using Li’s minimum cross-entropy thresholding
method, a function of the Auto Threshold plugin. ROIs were se-
lected and drawn as described for Iba-1 stereology and silver
staining. The summarize function under analyze particles was used
to acquire the area fraction occupied by positive GFAP signal.
These values were averaged from three serial sections, and the
resulting value is reported.
Quantitative polymerase chain reaction
Quantitative polymerase chain reaction (qPCR) was performed
to determine gene expression levels of interleukin (IL)-1b, IL-6,
inducible nitric oxide synthetase (iNOS), chemokine (C-C motif )
ligand 2 (CCL2), and tumor necrosis factor alpha (TNF-a). Im-
mediately after sacrifice, brains were harvested and a 2-mm coro-
nal slice was collected. The anteriormost portion of the slice
FIG. 7. Amyloid precursor protein (APP) and neurofilament (RM014) labeling in an injured CD11b-TK - / - mouse treated
with 10mg/mL of valganciclovir and sacrificed 7 days postinjury. APP and labeling was prominent at the site of cannulation (dashed
line) - 0.5mm relative to bregma (A and B). Only sparse axonal swellings were detectable in the contralateral hemisphere (injured
side) in the corpus callosum and external capsule corresponding to the region of interest assessed for axonal injury in these
experiments (C and D). Insets show higher magnification of labeling in boxed regions in (A) and (C). TK, thymidine kinase. Color
image is available online at www.liebertpub.com/neu
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corresponded to the anterior end of the hippocampus. The section was
further dissected by making a cut parallel to the interface between the
hippocampus and thalamus, and only the dorsal portion (approxi-
mately 30mg) was reserved for qPCR. Sections were frozen on
crushed dry ice and stored at -80C. Tissue was later lysed in Qiazol
(Qiagen, Jena, Germany) and disrupted using a rotor-stator homog-
enizer, following the manufacturer’s protocol for homogenization of
fatty tissues. The final RNA pellet was resuspended in 100lL of
RNAse-free water and further purified using an RNeasyKit (Qiagen).
DNAse was applied to the column to remove genomic DNA con-
tamination. For complementary DNA (cDNA) preparation, 1lg of
RNA was used in each RNA-cDNA reaction (High Capacity RNA-
to-cDNA Kit; Applied Biosystems, Foster City, CA). For each qPCR
reaction, 1lL of undiluted cDNAwas added to 15lL of Syber Green
PCRMaster Mix (Applied Biosystems), 13 uL of ddH20, and 1lL of
10-mM forward and reverse primers (Table 1). Samples were loaded
on a MicroAmp Fast Optical 96-Well Reaction Plate (Applied Bio-
systems), and qPCR was carried out on a 7500 Fast Real-Time PCR
System (Applied Biosystems). The following conditions were used:
95C for 10min followed by 40 cycles of 95C for 15 sec and 60C
for 1min.
DDCt values were calculated by normalizing the expression of
each gene to the geometric mean of three reference genes (hprt,
pgk1, and gapdh). Subsequently, these target gene values were
normalized to the arithmentic mean values in untreated naı¨ve mice
(n = 4). Exponential transform was performed to achieve fold-
change measures of each gene, where 1 is equal to naı¨ve mice.
Data analysis and statistics
All data were analyzed and graphed using GraphPad Prism soft-
ware (GraphPad Software Inc., San Diego, CA). Shapiro-Wilks’
normality tests were applied to determinewhether data were normally
distributed. Rank transformations were applied to data that failed
FIG. 8. Normal axonal ultrastructure in a cannulated shamCD11b-TK- /- mouse treated with 10mg/mL of valganciclovir and sacrificed 7
days post–sham injury. (A and B) Axons in the corpus callosum near the cingulum display organized cytoskeletal elements and intact myelin
sheaths. (C) Region containing axons cut parallel to the predominant direction of the corpus callosum. Asterisk (*) indicates a swollen
unmyelinated axon with abnormal organelle accumulation. Note nearby axons appear relatively intact, however. TK, thymidine kinase.
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normality tests. In experiments with two test groups, Student’s t-tests
were used. Two-way analyses of variance (ANOVAs) were used in
all other cases except analysis of sham mice with or without cannu-
lation, in which case a one-way ANOVA was performed. Post-hoc
comparisons between CD11b-TK+ /- and CD11b-TK- /- mice as
well as between saline- and valganciclovir-treated CD11b-TK+ /-
mice were prespecified. Statistical significance was defined as
p< 0.05 for t-tests and ANOVAs and p<0.0167 for post-hoc tests.
Results
Acute effects of microglia on axonal injury in mice
receiving low-dose valganciclovir (7 days)
Previous reports indicate that daily systemic administration of
valganciclovir causes hematopoetic toxicity and is fatal to CD11b-
TK+ / - mice within 10 days.31 On the other hand, delivery of the
drug directly into the brain can result inmicroglial reductionwithout
the toxicity observed after i.p. injection.34 Continuous administra-
tion is required because macrophages will rapidly repopulate areas
of microglial depletion in the absence of the drug.35 Because our
goal was to test the effects of microglial depletion on axonal injury
at time points between 1 week and 1 month after injury, we chose to
administer valganciclovir continuously by i.c.v. osmotic pump.
However, because there is deformation of the brain during the brain
injury, we chose to remove the pumps during the 24 h required for
the rcTBI procedure to prevent additional injury of the brain caused
by the cannula (Fig. 1). For initial experiments, a valganciclovir
concentration of 1mg/mLwas chosen because it has been shown by
other groups to be effective in reducing microglial cells.34,36
FIG. 9. Ultrastructural abnormalities in an injured CD11b-TK - / - littermate control mouse treated with 10mg/mL of valganciclovir
and sacrificed 7 days postinjury. (A) Arrowheads indicate regions of end-stage axonal degeneration in corpus callosum near the
cingulum where the axolemma has completely collapsed. Asterisks (*) denote examples of myelinated and unmyelinated axons with
organelle accumulation. (B) Myelinated axon undergoing Wallerian degeneration (asterisk). (C) Region of relatively healthy appearing
axons in corpus callosum. rcTBI, repetitive closed-skull traumatic brain injury; TK, thymidine kinase.
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Within the ipsilateral CC and EC, treated CD11b-TK+ /- mice
(n=13) had a 35% reduction in the number of microglial cells,
compared to littermate controls (n=11) at the 7-day time point after
injury (one-tailed Student’s t-test, p=0.008; Fig. 2A–D,G). To con-
trol for the effects of injection of vehicle alone, the experiment was
repeated with additional groups that received 0.9% NaCl (Fig. 3A;
CD11b+ /- valganciclovir n=9, NaCl n=7; CD11b-TK- /- val-
ganciclovir n=6, NaCl n=8). An effect of genotype (p=0.0359)
and treatment ( p= 0.0226) was noted, but not an effect of geno-
type · treatment (two-way ANOVA, p = 0.1039; Fig. 3A). Pre-
specified, planned comparisons revealed a significant difference
between valganciclovir-treated CD11b-TK+ / - versus littermate
controls ( p = 0.0110; Fig. 3A), no difference between the two ge-
notypes receiving vehicle alone ( p= 0.7096), and a significant
difference between CD11b-TK + / - valganciclovir- and vehicle-
treated mice ( p= 0.0057).
We then used silver staining to assess injured axons in mice
with reduced numbers of microglia. No difference in the inten-
sity or distribution of silver staining was observed in either the
first (two-tailed Student’s t-test, p = 0.8292; Fig. 2E,F,H) or the
second groups of mice (two-way ANOVA, genotype p = 0.8478,
treatment p = 0.6147, genotype · treatment p = 0.2769; Fig. 3B).
We have previously shown that silver staining is a sensitive
method to assess axonal injury in this repetitive concussive in-
jury model.29
Dose-response of microglia to valganciclovir
treatment in CD11b-TK mice
We reasoned that a modest reduction in the number of microglial
cells within the WMmay not be adequate to produce an effect on the
extent of axonal injury. We therefore next tested higher doses of
FIG. 10. Ultrastructural abnormalities in an injured CD11b-TK+ /- mouse treated with 10mg/mL of valganciclovir and sacrificed 7 days
postinjury. (A) Arrowhead indicates an example of end-stage axon degeneration in corpus callosum near the cingulum where the
axolemma has completely collapsed. Asterisk (*) denotes a swollen axon undergoing late-stage degeneration, and arrows indicate examples
of axons containing densely packed intracellular aggregates. (B) Arrow indicates an axon cut parallel to the predominant direction of the
corpus callosum with abnormal accumulation of electron-dense intra-axoplasmic material in a region of relatively normal axons (asterisk).
(C) Asterisk indicates an axon undergoing axolemma collapse. rcTBI, repetitive closed-skull traumatic brain injury; TK, thymidine kinase.
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valganciclovir in mice that received rcTBI to increase the amount of
microglial depletion. Using the same injection paradigm as before,
mice were treated with either 2 (n=3), 5 (n=3), 10 (n=5), or 50mg/
mL (n=8) of valganciclovir (Figs. 4 and 5). At 5–7 days postinjury
(14 days after initial pump implantation), CD11b-TK+ /- mice in the
50-mg/mL group became lethargic, had difficultywalking, and a 50%
mortality rate. WT littermate controls treated identically with 50mg/
mL of valganciclovir (n=6) appeared normal. Upon histological
examination, intraparenchymal hemmorhages and extensive tissue
loss within the hippocampus and thalamus were apparent in treated
CD11b-TK+ /- mice (Fig. 4A,B). Mice that received intermediate
doses of 2, 5, or 10mg/mL appeared normal physically and histo-
logically (Fig. 5A–F). Therefore, 10mg/mL was selected for future
experiments because this dose consistently resulted in microglial
depletion in the hemisphere opposite injection near the CC and EC
(Fig. 5E,F).
FIG. 11. Treatment with low-dose valganciclovir (1mg/mL), but not saline, reduces Iba-1, but not silver staining in corpus callosum
21 days after repetitive closed-skull traumatic brain injury. Iba-1 staining in valganciclovir-treated CD11b-TK - / - (A) and CD11b-
TK + / - (B) mice. Silver staining in valganciclovir-treated CD11b-TK - / - (C) and CD11b-TK+ / - (D) mice. (E) Iba-1 was reduced by
35% in CD11b-TK + / - mice, compared to CD11b-TK–/– controls (one-tailed Student’s t-test; **p < 0.01). (F) No change in silver
staining was observed. A.U., arbitrary units; n.s., not significant. Error bars represent standard error of the mean. TK, thymidine kinase.
Color image is available online at www.liebertpub.com/neu
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Acute effects of intermediate-dose valganciclovir
on axonal injury (7 days)
A separate cohort of mice was treated with 10mg/mL of val-
ganciclovir and examined 7 days after rcTBI (Fig. 6A–F). At 7 days
postinjury, the number of Iba-1-positive cells within the CC and EC
ipsilateral to injury was 56% reduced in CD11b-TK + / - (n = 7),
compared to littermate controls (n= 7; one-tailed Student’s t-test,
p = 0.0004; Fig. 6A,B,E). Again, no significant reduction in the
amount of silver staining was observed (two-tailed Student’s t-test,
p = 0.6045; Fig. 6C,D,F).
To determine whether other aspects of axonal injury were af-
fected by microglial depletion, other injury markers were assayed
in adjacent tissue sections for APP and neurofilament compaction
(Fig. 7A–D). APP is a marker of fast axonal transport that accu-
mulates in axonal swellings within hours of axonal injury.37,38 The
neurofilament Ab, RM014, has been used to detect neurofilament
compaction, an indicator of cytoskeletal disruption in degenerating
axons.39 Both of these markers were present near the site of can-
nulation in all mice (Fig. 7A,B), but were sparse and detected
infrequently in more-posterior regions ipsilateral to injury (Fig.
7C,D). Most commonly, they occurred in WM tracts overlying the
lateral ventricle, which may be a particularly vulnerable region in
this model. However, no qualitative difference was observed be-
tween genotypes, indicating that these markers of axonal injury
were not affected by microglial depletion.
To further confirm that no subtle alterations in axonal injury
severity are occurring after microglial depletion, qualitative elec-
tron microscopy was carried out in a sham littermate control treated
with 10mg/mL of valganciclovir (n = 1; Fig. 8A–C), injured lit-
termate controls treated with 10mg/mL of valganciclovir (n= 2;
Fig. 9A–C), or CD11b-TK + / - mice treated with 10mg/mL of
valganciclovir (n= 2; Fig. 10A–C). The frequency and character-
istics of axonal injury 7 days postinjury were assessed. The CC and
EC ipsilateral to injury directly beneath the impact site were ana-
lyzed. In sham injury with 10mg/mL of valganciclovir treatment,
most axons displayed a normal appearance, with intact myelin
sheaths and regularly spaced microtubules and neurofilaments (Fig.
8A,B). However, occasional swollen axons displayed organelle
accumulation consistent with injury and were likely artifacts of
cannulation (Fig. 8C). In contrast, the effects of repetitive con-
cussive TBI were more dramatic. In both CD11b-TK + / - and
CD11b-TK - / - mice injured and treated with valganciclovir, axo-
nal injury was a prominent feature within the CC and EC. Notably,
small myelinated axons displayed abnormal morphology with or-
ganelle accumulation, cytoskeletal disorganization, and axolemma
collapse (Figs. 9 and 10). These features are all consistent with
Wallerian degeneration. Overall, injury levels were approximately
the same as reported previously in this model.29 No overt differ-
ences were detected between CD11b-TK + / - and CD11b-TK- / -
mice. These observations were confirmed by a second, blinded
observer (Dr. Krikor Dikranian). These observations further indi-
cate that axonal injury was not affected by microglial depletion.
Subacute effects of low- and intermediate-dose
valganciclovir on axonal injury (21 days)
Next, we sought to determine whether longer-term reduction of
microglia alters the evolution of axonal injury over time (Figs. 11
and 12). We have previously reported that silver staining abnor-
malities persist out to 49 days (the longest time point analyzed).29
We chose to analyze mice at 21 days postinjury because this would
allow us to treat mice with valganciclovir for 1 month (28 days) and
would not require that the osmotic pumps to be replaced—a pro-
cedure requiring additional surgery. In the low-dose experiment,
mice were treated with 1mg/mL of valganciclovir (CD11b + / -
n = 7, CD11b - / - n = 6) or 0.9% NaCl (CD11b + / - n = 5, CD11b - / -
n = 5; Fig. 11). Overall, analysis of microglial activation by two-way
FIG. 12. Subacute treatment with intermediate-dose valganciclovir is toxic in injured CD11b-TK mice. Twenty-eight days total
treatment resulted in tissue loss, as visualized by cresyl violet, in hippocampus and thalamus of injured CD11b-TK + / - (A), but not
CD11b-TK - / - (B), mice. Iba-1 staining shows extent of microglial depletion in CD11b-TK+ / - (C) and not in a CD11b-TK - / - (D)
littermate control mouse subjected to repetitive closed-skull traumatic brain injury. TK, thymidine kinase. Color image is available
online at www.liebertpub.com/neu
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ANOVA revealed no effect of genotype ( p= 0.3307) or treatment
( p = 0.9511), but a significant genotype · treatment interaction
( p = 0.0118). Additionally, a significant reduction of microglial
cells in the CC and EC of approximately 35% in valganciclovir-
treated CD11b-TK + / - mice, compared to valganciclovir-treated
littermate controls, was observed ( p= 0.0099; Fig. 11A,B,E). No
difference was observed in NaCl-treated mice between genotypes
( p = 0.2488). The difference between microglial cells in valganci-
clovir-treated versus NaCl-treated CD11b-TK+ / - mice was not
quite statistically significant ( p = 0.0547; Fig. 11E). Again, as in the
acute experiments, no difference was observed across groups in the
amount of silver staining (Fig. 11C,D,F).
An additional group of either CD11b-TK + / - mice (n= 6) or
littermate controls (n= 8) received 10mg/mL of valganciclovir and
was sacrificed 21 days postinjury (Fig. 12A–D). Though the mice
did not display an overtly abnormal behavioral phenotype, histo-
logical examination revealed tissue loss similar to that observed
with the 50-mg/mL dose. Thus, the duration of drug administration
at intermediate doses can also produce a toxic effect in CD11b-TK
mice. Because of the clear toxicity of the drug, Iba-1 and silver
staining were not quantified in these animals.
Terminal deoxynucleotidyl transferase dUTP
nick end labeling labeling in mice treated
with intermediate-dose valganciclovir
Given the apparent toxicity of intermediate-dose valganciclovir
(10mg/mL) in CD11b-TK mice treated for 21 days postinjury, we
performed TUNEL labeling to determine whether this intermediate
dose induces apoptosis in neurons 7 days postinjury (Fig. 13A,B).
Sections from CD11b-TK+ / - (n = 7) and CD11b-TK - / - (n= 7)
mice treated with valganciclovir were double labeled for TUNEL
and NeuN, a neuron-specific marker. The hippocampal CA3 ipsi-
lateral to cannulation and drug infusion was the focus of these
investigations because this is a region significantly affected by
toxicity 21 days postinjury. However, no apoptotic neurons were
detected here at 7 days postinjury. This would indicate that neu-
rodegeneration begins later than day 7 postinjury. As a positive
control to assess the sensitivity of our TUNEL labeling, we treated
adjacent sections with DNAse I to induce DNA nicks. This caused
prominent TUNEL staining (Fig. 13C). Thus, the lack of TUNEL
staining in the valganciclovir-treated CD11b-TK + / - mice is likely
to accurately indicate a lack of apoptotic injury.
Effect of cannulation on silver staining
To determine whether cannulation produces axonal injury that
may be masking the potentially beneficial effects of microglial
depletion, we next determined the level of silver staining in CD11b-
TK- /- sham mice alone (n= 5; Fig. 14A,C), CD11b-TK- /- sham
mice receiving i.c.v. saline by osmotic pump (n= 5; Fig. 14B,D),
and CD11b-TK+ /- sham mice receiving intermediate-dose val-
ganciclovir by osmotic pump (n= 5; Fig. 14E,G). No difference was
observed between groups (one-way ANOVA, p= 0.7006; Fig. 14F).
This indicates that contralateral cerebroventricular cannulation did
not produce significant axonal injury in the ipsilateral CC ROI.
Astrocyte response in valganciclovir-treated mice
To confirm that only microglial numbers are being altered in this
model, we analyzed the numbers of GFAP-positive astrocytes in
regions of microglial depletion. We did not observe any change in
the numbers of GFAP-positive astrocytes in the CC and EC of mice
treated with 1mg/mL of valganciclovir or 0.9% NaCl for 14 days
(two-way ANOVA, genotype p= 0.6028, treatment p= 0.9339,
genotype · treatment p = 0.7852; Fig. 15A–C). Similarly, there
were no apparent changes in astrocytes resulting from valganci-
clovir treatment within gray matter areas.
Inflammatory response in valganciclovir-treated mice
To determine how the inflammatory response was affected by
microglial depletion in the setting of TBI, RNA was purified from
injured and uninjured mice acutely treated (14 days total) with
10mg/mL of valganciclovir and the amount of TNF-a, IL-1b, IL-6,
iNOS, and CCL2 messenger RNA (mRNA) was determined by
qPCR (Fig. 16A–E). Injury alone appeared to result in, at most,
modest ( < 5-fold) increases in expression of these genes (rcTBI vs.
sham CD11b - / - mice; Fig. 16A–E). Surprisingly, treatment of
CD11b + / - mice with valganciclovir produced substantially greater
changes in inflammatory gene expression in both injured and
FIG. 13. Double immunofluorescence for TUNEL (green) and
NeuN (red) in the hippocampal CA3 does not indicate neuronal
apoptosis in injured mice treated with 10mg/mL of valganciclovir
and sacrificed 7 days postinjury. TUNEL labeling was not ob-
served in NeuN + cells in the hippocampal CA3 of CD11b - / - (A)
or CD11b + / - (B) mice. A positive control for TUNEL labeling
was generated by incubating a more anterior section (cortical re-
gion) in DNAse I to induce double-stranded DNA breaks (C). All
images were acquired using the same settings on a laser scanning
confocal microscope. TUNEL, terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling; NeuN, neuronal nuclear antigen.
Color image is available online at www.liebertpub.com/neu
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uninjured mice. Qualitatively, only TNF-a appears to be increased
to a greater extent in CD11b-TK + / - injured versus uninjured mice
(Fig. 16E). Thus, whereas valganciclovir treatment of CD11b-TK
mice reduces microglial cells, it may also drastically alter the in-
flammatory environment in this model.
Discussion
In summary, we found that a reduction of the microglial popu-
lation within the CC and EC by 35–56% neither increases nor
decreases the extent of silver staining abnormalities. The most
likely interpretation is that while microglia migrate to, and prolif-
erate around, areas of axonal injury, overall they remain neutral in
regard to the early processes of axon degeneration. We also provide
further evidence that the CD11b-TK mouse line is a powerful tool
for manipulating the microglial and macrophage response, but
show that the dose of valganciclovir must be carefully determined
to prevent unintended, nonspecific toxicity and altered inflamma-
tory gene expression in the central nervous system.
These studies are important because, to our knowledge, there are
no previous reports directly addressing the relationship between
microglia and axon injury after in vivo mild repetitive TBI. Re-
searchers have used minocycline to reduce microglial activation,
where it was reported to reduce brain lesion volume, caspase 1 ac-
tivation, and cerebral edema after closed-skull TBI in mouse.40–43
However, only one of these studies measured axonal injury (by APP
IHC), and similar to results reported here, no difference was ob-
served between minocycline- and vehicle-treated mice, despite a
59% reduction in microglial activation.43 In another study in rats,
administration of ‘‘anti-inflammatory’’ doses of ibuprofen for 4
months post–moderate fluid percussion TBI worsened performance
on Morris water maze, a test of spatial learning and memory, com-
pared to vehicle-treated rats.44 The effect of treatment on micro-
gliosis and axonal injury were not assessed. In the present study, we
similarly reduced the number of microglia present in WM tracts and
assayed axonal injury using multiple injury markers and electron
microscopy. This study is limited, however, in that we cannot rule
out the possibility of functional consequences to the depletion of
microglia, independent of histological abnormalities.45 In addition,
this study is also limited in that it is possible that the maximum
reduction of the microglial population by 56% was not enough to
produce an effect onWM integrity. The remaining microglia may be
able to compensate for the loss by ramping up production of secreted
factors. Indeed, qPCR analysis revealed considerably more TNF-a,
IL1-b, IL-6, iNOS, and CCL2mRNA after valganciclovir treatment.
These factors may directly impair axons or modulate the inflam-
matory response in a complex fashion.46–48 Given this increase, it is
FIG. 15. Astrocytes 7 days after repetitive closed-skull trau-
matic brain injury in mice treated with 1mg/mL of valganciclovir
or NaCl. GFAP staining in treated CD11b-TK- / - (A) and
CD11b-TK + / - (B) mice. (C) No differences in GFAP optical
density was observed between groups. GFAP, glial fibrillary
acidic protein; TK, thymidine kinase. Color image is available
online at www.liebertpub.com/neu
FIG. 14. Right-sided cerebroventricular cannulation does not
contribute to silver staining in the left corpus callosum region of
interest assessed for axonal injury. Silver staining was performed in
sections from CD11b-TK- /- mice that underwent the sham pro-
cedure alone (A and C) or the sham procedure plus cannulation and
treatment with saline (NaCl; B and D). Silver staining was also
performed in sections from CD11b-TK+ /- mice that underwent the
sham procedure plus cannulation and treatment with 10mg/mL of
valganciclovir (E and G). All mice were sacrificed 7 days post–
sham injury. (F) No difference in silver staining was observed
between groups. A.U., arbitrary units; TK, thymidine kinase. Color
image is available online at www.liebertpub.com/neu
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remarkable that more-severe silver staining abnormalities were not
detected. This could indicate that axons are resilient to many aspects
of the inflammatory response. An important line of future investi-
gation will involve elucidating the full time course of the changes in
cytokine expression in response to injury and valganciclovir ad-
ministration. Whether microglia and macrophages were directly
responsible for the increases in secreted cytokine mRNA or whether
the reduction inmicroglia induced expression by other cell types was
not examined. Another alternative explanation for our results is that
there could be both beneficial and harmful subtypes of microglia that
are approximately evenly reduced by the experimental manipula-
tions resulting in a net neutral effect on WM.49 A final alternative
explanation could be that any beneficial effects of microglial re-
duction were offset by the up-regulation of inflammatory gene ex-
pression in response to the valganciclovir treatment.
This study was also limited in that it did not assess the specific
contribution of the resident microglial population versus peripheral
macrophages to injury. In this injury model, however, we have not
observed IgG accumulation or a large population of CD45 + hi,
CD11b + cells (unpublished observations) that would be indicative
of infiltration of peripheral macrophages. Thus, while peripheral
macrophages may be present in rcTBI brains, most Iba-1 positive
cells are likely resident microglia.
Although these data indicate that microglial cells are likely
neutral overall in regard to axon injury after repetitive concussion
in the acute and subacute phase, it remains mysterious why mi-
croglial cells migrate to the CC and EC and remain activated
over the long term. Activated microglia and macrophage have
been observed in the CC and other brain regions in human TBI
patients several months or years after injury, indicating this is not a
FIG. 16. qPCR measurement of inflammatory gene expression. Relative expression of (A) Ccl2, (B) Il1b, (C) Il6, (D) iNOS, and (E)
Tnfa in each mouse was normalized first to the geometric mean of 3 reference genes (Hprt, Pgk1, Gapdh) and then to arithmetic mean of
the uninjured, naı¨ve mice (n = 4; dashed line). CCL2, chemokine (C-C motif ) ligand 2; IL, interleukin; iNOS, inducible nitric oxide
synthetase; TNF-a, tumor necrosis factor alpha; rcTBI, repetitive closed-skull traumatic brain injury; TK, thymidine kinase. Color
image is available online at www.liebertpub.com/neu
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mouse-specific phenomenon.10,16,23 Because these are phagocytic
cells, it may be that ongoing axon degeneration results in debris that
stimulates the microglial response. Microglial clearance of this
debris may be neither beneficial nor harmful in the relatively short
time scale assessed in these experiments, but could play an im-
portant role in long-term chronic sequelae of injury, including
axonal sprouting and regeneration not assessed here.50 Indeed,
microglia are important sources of brain-derived neurotrophic
factor and other neurotrophins that stimulate axonal sprouting and
may be central to recovery from injury.51,52 Future work may help
to address these questions and provide deeper insight into the bi-
ological function of microglia after injury. Other studies may also
address the effect of microglial reduction in more-severe brain
injury, where the role of microglial cells may be distinct.53,54
A technical note regarding the toxicity of valganciclovir in
CD11b-TK mice warrants discussion. It was surprising that valgan-
ciclovir administration at intermediate and high doses produced such
widespread tissue loss in CD11b-TK mice. Work from Grathwohl
and colleagues has previously reported that administration of 50mg/
mL of valganciclovir can producemicrohemorrhages after 1month of
treatment.36 Their group was using an independently derived line of
CD11b-TKmice.Mice used in our experiments were generated in the
lab of Jean-Pierre Julien, and the thymidine kinase gene contains a
mutation resulting in increased sensitivity to drug treatment. This
increased sensitivity could explain why 10mg/mL was sufficient to
produce toxicity after 28 days and 50mg/mL increased mortality by
50% after 14 days of treatment in our experiments. The underlying
cause of this toxicity is unknown; the profoundly up-regulated cy-
tokine mRNA levels detected by qPCRmay indicate either a cause or
an effect of the toxicity.
Altogether, the finding that microglia appear to be neutral in
regard to injury is an important consideration for the design of future
therapeutics. This could indicate that drugs specifically targeting
axonal injurymay bemore useful after concussive-type injuries than
those targeting microglial cells. Alternatively, methods to more
completely prevent the activation and/or proliferation of microglial
cells without toxicity should be sought for further studies.
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